Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


ZC(=O)OY, wherein Z is an acyclic radical bonded to the C=O by a carbon and Y is an organic radical bonded to the oxygen by a carbon

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514506000 - Ester DOAI

514529000 - Z-C(=O)-O-Y wherein Z is hydrogen or an organic radical bonded to the C(=O) by a carbon and Y is an organic radical bonded to the oxygen by a carbon

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514547000 Compound contains two or more C(=O)O groups 143
514549000 Z radical contains carbon to carbon unsaturation 76
514552000 Z contains an unbroken chain of at least seven carbon atoms bonded directly to the C(=O) group 39
514551000 Z radical contains nitrogen 34
514550000 Z radical contains sulfur or halogen 4
20090156674Valnemulin Salts with Organic Acids - The invention relates to the production of a new salt form of valnemulin, a compound of formula I, which is notable for its good crystallinity in higher purity, its simpler technical usability and improved storage stability.06-18-2009
20090143467ANTICANCER AGENTS BASED ON REGULATION OF PROTEIN PRENYLATION - Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the protein in the presence of an enzyme (e.g. farnesyl protein transferase). Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.06-04-2009
20090186941ORGANIC SULFUR COMPOUNDS AND USE THEREOF - A compound given by the formula (I):07-23-2009
20100160434ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD - There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods represented by the formula (I): wherein, R06-24-2010
Entries
DocumentTitleDate
20100137435Monoacetyldiacylglycerol Derivative for the Treatment of Sepsis - The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against caner cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect of apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer.06-03-2010
20100029764COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE-MEDIATED INTRACELLULAR SIGNAL TRANSDUCTION - Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide compositions and methods suitable for modulation of at least one of cellular membrane potential and cellular membrane conductivity. Additional aspects provide compositions and methods suitable for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically altered solutions to impart electrochemical and/or conformational changes in membranous structures (e.g., membrane proteins, receptors and/or other components) including G-protein coupled receptors (GPCRs), G-proteins, and/or intracellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).02-04-2010
20090192223GIP SECRETION INHIBITOR - The object of the invention is to provide a GIP secretion inhibitor which is a useful drug or food ingredient. The present invention provides an agent for inhibiting postprandial GIP secretion contains a monoacylglycerol as an active ingredient.07-30-2009
20090192224CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF - The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C07-30-2009
20100076080Synthesis of Cyclohexane Derivatives Useful as Sensates in Consumer Products - The present invention provides synthetic routes for preparing various isomers of cyclohexane-based coolants, such as menthyl esters and menthanecarboxamide derivatives, in particular those substituted at the amide nitrogen, for example with an aromatic ring or aryl moiety. Such structures have high cooling potency and long lasting sensory effect, which make them useful in a wide variety of consumer products. One synthetic route involves a copper catalyzed coupling of a primary menthanecarboxamide with an aryl halide, such reaction working best in the presence of potassium phosphate and water. Using this synthetic route, specific isomers can be prepared including the menthanecarboxamide isomer having the same configuration as l-menthol and new isomers such as a neoisomer having opposite stereochemistry at the carboxamide (C-1) position. The neoisomer unexpectedly has potent and long lasting cooling effect. Preparation schemes for neoisomers of other menthyl derivatives which are useful as coolants, including esters, ethers, carboxy esters and other N-substituted carboxamides are also provided.03-25-2010
20130079405Hydroxy Acid Ester Compound of Substituted Phenol, Preparation Method and Medical Use Thereof - Hydroxy acid compound of substituted phenyl ester, preparation method and medical use thereof are provided. The title compound is shown in formula (I), Y═C03-28-2013
20090156672Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities - Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include one or more substituted phenyl aziridine precursors, their respective aziridines, analogs thereof, derivatives thereof, or pharmaceutically acceptable salts thereof such as CpdA. The methods and compositions may be used for treating diseases, disorders, and conditions associated with glucocorticoid receptor activity, androgen receptor activity, or both, such as cancers, acne vulgaris, and alopecia.06-18-2009
20090124691INHIBITOR OF INCREASE IN POSTPRANDIAL BLOOD INSULIN LEVEL - The present invention provides an agent for inhibiting a postprandial increase in blood insulin level, wherein the agent containing a monoacylglycerol as an active ingredient. An agent of the invention for inhibiting a postprandial increase in blood insulin level contains a monoacylglycerol as an active ingredient.05-14-2009
20130072558METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION - A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C03-21-2013
20130072556RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS - Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.03-21-2013
20130072557METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION - A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C03-21-2013
20110028546NOVEL ANTIMICROBIAL FORMULATIONS INCORPORATING ALKYL ESTERS OF FATTY ACIDS AND NANOEMULSIONS THEREOF - The present invention relates to a novel antimicrobial composition and method comprising any of the C1-C4 monohydric alcohol esters of C8 to C22 fatty acids, and most preferably the C1-C4 monohydric alcohol esters of C8 to C12 fatty acids, namely, caprylic, capric, and lauric fatty acids. Specifically the invention is related to a composition and method to disinfect various surfaces and substrates including the surfaces of food products, animal and human tissue and appendages, inanimate objects of various compositions, and also enclosed spaces. The invention can be incorporated into various media including liquids, gels, powders, paints, sealants, and the like and can be in the form of emulsions including nanoemulsions.02-03-2011
20110015267METHODS FOR THE PREPARATION AND USE OF AQUEOUS SOLUTIONS OF MAGNESIUM VALPROATE HYDRATE AND L-CARNITINE - The present invention relates to methods for preparing liquid valproate compositions comprising solutions of a magnesium valproate and L-carnitine in water and administering said compositions to a subject in need of treatment with valproate and L-carnitine. The compositions of the invention are particularly useful treatments for infants, young children, women of child-bearing age, the aging, institutionalized patients, and patients having dysphagia who are receiving valproate treatment and are at high risk for valproate-related L-carnitine deficiency and cellular dysfunction and hepatotoxicity related thereto.01-20-2011
20080306152COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE - The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration.12-11-2008
20090082443Use of fatty acid esters of glycerol combined with polylysine against gram-negative bacteria - The present invention relates to a method for the prevention and/or reduction of the presence, growth and/or activity of gram-negative bacteria comprising application of a composition comprising glycerol-based fatty acid esters and polylysine and/or salts of polylysine, wherein said glycerol-based fatty acid ester is used as antibacterial agent. The present invention further relates to the use of said composition as antibacterial agent in various products and applications ranging from technical products and personal-care products to food and drink products for animals and human consumption.03-26-2009
20110294882NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES - The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.12-01-2011
20100249230ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES - Disclosed is a method of synthesizing new optically pure heterocyclic compounds using Pd(0) catalyzed intramolecular cyclizations. Analogs of cyclopentanes, like isoxazoline-2-oxide and furan, with similar framework to the cyclopentanes act as anti-HIV and anticancer agents which opens a whole new field for application of these compounds. Starting from a meso-diol, optically pure compounds were prepared without utilizing chiral ligands at any stage of the synthesis. The stereochemical outcome of the product (>99% ee) was influenced by desymmetrization catalyzed by 09-30-2010
20100099762COMBINATION THERAPY - The present invention relates generally to a method of treating a psychiatric or neuropsychiatric condition in a mammal with a combination therapy. More particularly, the present invention relates to a combination therapy comprising an antipsychotic agent and a compound that increases levels of glutathione in the body.04-22-2010
20110172304Sex Attractant of White Peach Scale and Attraction Method - Provided is an attractant of white peach scale capable of simplifying the synthesis of a sex pheromone of white peach scale and suppressing attraction of a parasitoid wasp which is a natural enemy of the white peach scale. More specifically, provided is a sex attractant of white peach scale comprising at least (R,Z)-(+)-3,9-dimethyl-6-isopropenyl-3,9-decadienyl priopionate and a geometric isomer (R,E)-(+)-3,9-dimethyl-6-isopropenyl-3,9-decadienyl priopionate at a weight ratio ranging from 80:20 to 40:60. In addition, provided is a method for attracting white peach scale by using said attractant.07-14-2011
20090012162Composition for treating or preventing cell degeneration using at least one molecule capable of maintaining adhesion molecule expression reversibility and vascular endothelium actin fibre polymerisation - The invention relates to the use of a molecule selected from the group which consists of geranyl acetate, geraniol, isomenthone, limonene or a mixture of at least two of the above, for preparing a drug for treating or preventing vascular endothelial cell senescence and subjacent tissue degeneration induced by repeated inflammatory episodes. Specifically, the drug is useful for treating vascular endothelial cell senescence and tissue degeneration induced by repeated inflammatory episodes resulting from the presence of cancer cells.01-08-2009
20090042982METHOD FOR TREATING NEUROLOGICAL DISORDERS USING ACETONE DERIVATIVES - The present invention provides a method of treating neurological disorders, such as epilepsy, comprising administering an effect amount of an acetone derivative having the formula R02-12-2009
20120295972Ester Derivatives of Bimatoprost Compositions and Methods - Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.11-22-2012
20100137434Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer - The present disclosure relates to the discovery that compounds of the invention, particularly 3-bromopyruvate and related compounds, can be safely administered at concentrations effective for the treatment of cancer when formulated with an acidity of greater than or equal to pH of 2 and less than or equal to a pH of 6. Disclosed herein are novel and improved methods and compositions for the treatment of cancer using 3-halopyruvate and related compounds.06-03-2010
20080275117Compositions and Methods Comprising Boswellia Species - In certain aspects the invention features novel compositions and pharmaceutical preparations of the same. In certain embodiments, the compositions comprise α- and/or β-boswellic acid and/or their C-acetates in an amount greater than 65% by weight.11-06-2008
20110207818DISINFECTING AND ANTIMICROBIAL COMPOSITIONS - Broad spectrum disinfecting and microbicidal compositions of biodegradable and environmentally friendly compositions containing esters formed from fatty organic alcohols and fatty carboxylic acids. These compositions display activities against the most resistant microbial forms including bacterial spores. The preparations can be used in health care, food processing, personal care and other industries where the use of harsh oxidizing chemicals is undesirable.08-25-2011
20080262083ANTIBACTERIAL AGENTS - D-(threo)-1-aryl-2-disubstitutedacylamido-3-fluoro-1-propanol compounds compounds and analogues thereof (“Fenicol Compounds”), compositions comprising an effective amount of a Fenicol Compound, and methods for treating or preventing a bacterial infection in an animal comprising administering to an animal in need thereof an effective amount of a Fenicol Compound are disclosed.10-23-2008
20090105337Esters of Florfenicol - The invention relates to compounds of formula (I):04-23-2009
20090239947Inhibition of proliferation and fibrotic response of activated corneal stromal cells - Provided herein are methods of preventing a fibrotic response and/or scarring in a wound, comprising administering to a subject a composition comprising an amount of an amide or ester of an alpha-ketoalkanoic acid effective to inhibit a proliferative and/or fibrotic response in the wound. In one instance, the wound is to a subject's cornea, such as a wound resulting from refractive surgery. In one embodiment, the amide or ester of an alpha-ketoalkanoic acid is ethyl pyruvate.09-24-2009
20090221702COMPOUNDS - The present invention provides the use of a compound of the Formula: (I) wherein R09-03-2009
20100184857ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATION AND THE TREATMENT OR PREVENTION OF GASTRIC TOXICITY - The invention provides hops (07-22-2010
20090170940Modified ethyl formate compositions and methods for soil fumigation - Slow-flow, modified ethyl formate compositions and methods for their use as pre-plant soil fumigants (controlling nematodes and other pathogens) are provided. The modifications include adding to ethyl formate a viscosity modifying thickening agent, and one or more substances which function as a co-solvent and dilution agent (the co-solvent and dilution may or may not be the same). The thickening agent increases the viscosity thereby slowing its flow or rate of transport through the soil. The co-solvent functions as the primary solvent for the viscosity modifying thickening agent. The dilution agent does two things. First, it is used to reduce the partial vapor pressure of the ethyl formate in the formulation, thereby slowing its evaporation rate. Second, it also slows the rate and amount of decomposition of the ethyl formate. The SFMEF compositions and methods do not have harmful ozone-depleting side effects and break down into two naturally-occurring, environmentally-friendly components. Thus they are useful as replacements for methyl bromide and other known ozone-depleting and/or highly toxic soil fumigants.07-02-2009
20090318552Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizo dor treating or preventing diabetes mellitus and the use thereof - The present invention relates to a composition for preventing and treating diabetes mellitus that includes a shikonin compound as an active ingredient and to a use thereof. More particularly, the present invention relates to a composition for preventing and treating diabetes mellitus that includes isobutyryl shikonin, β,β-dimethylacryl shikonin, isovaleryl shikonin, or α-methyl-n-butyryl shikonin as an active ingredient and to a use thereof. The composition of the present invention exhibits antidiabetic effects by blocking the K12-24-2009
20130131167BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS - This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss.05-23-2013
201301311681-MONOPROPIONINE COMPOUND AND ITS ISOMER 3-MONOPROPIONINE AS PRESERVING AGENTS FOR ANIMAL FEED, GRAINS AND ANIMAL-ORIGIN MEALS - An application method of 1-monopropionine compound and its isoform 3-monopropionine being used as preserving agents in animal feeds, corns, grains, and other food materials. The monopropionine compounds are obtained by esterification reaction of propionic acid and glycerol. The product is a translucent viscous liquid composition comprising monopropionine compounds and other components, such as free acid, or certain salt forms of propionate. The generated composition can be further distilled in glycerol. The final product can take a liquid form or a powder form. 1-monopropionine compound and its isoform 3-monopropionine function as preserving agent at a low effective dosage of about 0.05 to 1% (by weight), and preferably 0.1 to 0.3% (by weight). A preferable application condition of this method is to preserve animal feeds and corns under a low (about 2% to 12%) moisture condition.05-23-2013
20090069422COMPOSITION AND METHOD FOR INCREASING THE ANABOLIC STATE OF MUSCLE CELLS - A nutritional supplement comprising at least a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ingredients of the present nutritional supplement substantially simultaneously act to induce a anabolically-favorable state for muscle by substantially simultaneously maintaining blood and muscle physiological pH levels as well as increasing cellular concentrations of branched-chain amino acids. Both a composition and a method are provided by the present disclosure.03-12-2009
20110245337METHOD FOR ENHANCING THE DNA REPAIR PROCESS, TREATING DISORDERS ASSOCIATED WITH THE DNA REPAIR PROCESS, ENHANCING ANTITUMOR RESPONSE AND TREATING DISORDERS ASSOCIATED WITH ANTI-TUMOR RESPONSE IN MAMMALS BY ADMINISTERING PURIFIED QUINIC ACID AND/OR CARBOXY ALKYL ESTER - For use in mammals, methods for enhancing the anti-tumor response and treating disorders associated with anti-tumor response. The methods generally comprise non-topical administration of purified, isolated quinic acid alkyl acid or a carboxy alkyl ester with a non-toxic carrier or diluent.10-06-2011
20110034554COMPOSITIONS AND METHODS FOR TREATING MACULAR DEGENERATION - Methods of retarding formation of a lipofuscin pigment in the retina and of treating or ameliorating the effects of a disease characterized by an accumulation of a lipofuscin pigment in a retina are provided. These methods include the step of administering to a patient in need thereof a substituted C02-10-2011
20100311830Menthol Replacement - A method of producing in a composition adapted to be applied to the mucous membranes, the physiological effects of menthol at a reduced menthol concentration, by the partial replacement of menthol by a cooling and flavour blend, including 12-09-2010
20110152367PROCESS FOR THE PREPARATION OF FESOTERODINE WITH LOW IMPURITIES CONTENT - Disclosed is a process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having a low content of impurities such as tolterodine and tolterodine isobutyrate.06-23-2011
20100280109LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT - The present disclosure relates to lipid compounds of formula (I):11-04-2010
20100280110(3R)-L-MENTHYL 3-HYDROXYBUTYRATE, PROCESS FOR PRODUCING THE SAME, AND SENSATE COMPOSITION COMPRISING THE SAME - The present invention provides a cooling component or sensate component which has further strong cooling intensity and is excellent in the persistency or refresh-feeling and cool-feeling, a sensate composition comprising the same, and various products comprising the sensate composition. The present invention relates to, as a cooling component or sensate component, (3R)-1-menthyl 3-hydroxybutyrate represented by the following formula (I):11-04-2010
20100184858Hepatic fibrosis inhibitor - The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula:07-22-2010
20110257266Therapeutic Regimen and Methods for Treating or Ameliorating Visual Disorders Associated - Disclosed herein are therapeutic regimens for treating or ameliorating a visual disorder associate with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative or a pharmaceutically acceptable composition comprising a synthetic retinal derivative according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.10-20-2011
20100022643GAMMA-HYDROXYBUTYRATE COMPOSITIONS CONTAINING CARBOHYDRATE, LIPID OR AMINO ACID CARRIERS - The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, or can target specific organs. 01-28-2010
20090062385DEUTERIUM-ENRICHED FESOTERODINE - The present application describes deuterium-enriched fesoterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-05-2009
20080234371Non-hygroscopic L-carnitine salts - Stable and non-hygroscopic L-carnitine salts of organic acids are provided, each of which is present as a true complex salt, having the formula:09-25-2008
20090326068Therapeutics for Cancer using 3-Bromopyruvate and other Selective Inhibitors of ATP Production - The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production for use in the invention.12-31-2009
20090292018Dicarbonic Acid Derivatives, Metastasis Inhibitors and Agents Increasing Chemotherapeutic Activity of Anti-Tumor Preparations, Method for Enhancing the Cytostatic Efficiency and Metastasis Process Inhibiting Method - The invention relates to dicarbonic acid derivatives and concerns dicarbonic acid monooxydamines and dioxydamides, which are physiologically active substances and can be used as low-toxic and non-toxic agents for enhancing the anti-tumor and anti-metastasis effects of known cytostatics (cyclophosphane and cisplatin) in cytostatic chemotherapy of tumors.11-26-2009
20120316235MATING DISRUPTION METHOD USING ACETATE-CONTAINING MATING DISRUPTANT - Provided is a mating disruption method capable of bringing a stable and effective mating disruption result. Specifically provided is a mating disruption method comprising a step of starting to apply a mating disruptant after mating and oviposition of imagoes of the first generation of an insect pest are substantially over and before imagoes of the second generation of the insect pest emerge, the mating disruptant targeting at least one kind of insect pest which contains one or more kinds of acetates as a natural sex pheromone.12-13-2012
20120220655CRYSTALLINE FORMS OF FESOTERODINE FUMARATE AND FESOTERODINE BASE - Polymorphically pure crystalline forms of fesoterodine fumarate and fesoterodine base are described and characterized.08-30-2012
20120270942Spreading Active Agricultural Agents - Disclosed herein is a device for the application of agricultural active agents, wherein the device is suitable to be brought to the site of action in a manner temporally and spatially separated from the production process, and comprises a dispenser and non-water-soluble nanofibers and/or mesofibers charged with agricultural active agents. The polymers from which the nanofibers and/or mesofibers are made are preferably biodegradable. The agricultural active agents are selected from fungicides, herbicides, batericides, plant growth regulators and plant nutrients. These are preferably pheromones, kairomones and signaling substances. Furthermore, a method for the production of this device is disclosed, wherein the nanofibers and/or mesofibers charged with active agents are produced via electrospinning. The device is suitable to be used to bring agricultural active agents to the site of action in a manner temporally and spatially separated from the production of this device. The application is suitable to be carried out mechanically or automatically. This is preferably agricultural land used for fruit growing, viticulture, gardening or a commercial row crop. The device according to the present invention is particularly suitable to be used for the regulation of arthropods.10-25-2012
20110237666HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF - A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia.09-29-2011
20100204322METHOD OF TREATING AUTOIMMUNE DISEASES - A method of treating an autoimmune disease (for example, Systemic Lupus Erythematosus) comprises administering to the subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof. Methods of screening compounds useful for the treatment of autoimmune disease are also disclosed.08-12-2010
20120277315PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS - A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.11-01-2012
20110281945GASTRIC ACID SECRETION INHIBITOR, AND POTASSIUM CHANNEL INHIBITOR - To provide a drug, quasi-drug, food or drink that can act as a gastric acid secretion suppressant or a potassium channel inhibitor by including a composition that can be safely used and can be inexpensively produced. Each of these products contains one or more cooling sensation compositions that are compounds providing cooling sensation in an amount sufficient for exhibiting the efficacy thereof in a living body to which the product is administered.11-17-2011
20100130606PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.05-27-2010
20130172411STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present invention relates to stable pharmaceutical compositions comprising fesoterodine or salts thereof. In particular, the invention relates to pharmaceutical compositions of fesoterodine which does not contain sugar alcohols. The invention also relates to processes for making such compositions and use thereof in treating patients with urinary incontinence.07-04-2013
20080249168Pharmaceutical composition for gout - A composition for hyperuricemia disease or a related disorder, use thereof and method of using thereof are provided.10-09-2008
20130096192NOVEL COMPOSITONS AND METHODS - Described herein are compositions (e.g., a pharmaceutical composition) and compounds of formula I, and their use in the treatment and/or prevention of diseases and disorders.04-18-2013
20130102663NUTRITIONAL COMPOSITION - An organoleptically acceptable composition containing a ketone body or a ketone body precursor including a hydroxybutyrate ester and a flavouring is provided and gives improved palatability and user adherence to the intended dose regime. The flavouring may be a bitter flavouring and the composition may further contain an adsorbent for the ketone such that on ingestion, the bitterness of the composition may be masked. The composition may be in the form of a solid, gel or liquid and provides increased blood ketone levels and may be used in therapy or in treating muscle impairment or fatigue.04-25-2013
20080207752Poly (epsilon-caprolactone-co-methylmethacrylate), method for preparing the same using super critical fluid, and method for preparing therapeutic agent for skin diseases such as acne, atopy and athlete's foot comprising the same - A biodegradable polymer comprising a spherical poly (ε-caprolactone-co-methylmethacrylate) used in a therapeutic agent for skin diseases and a method for preparing the same, and a method for preparing the therapeutic agent for skin diseases having the particle size of 50 to 100 nm and a spherical shape comprising the poly (ε-caprolactone-co-methylmethacrylate) and salicylic acid.08-28-2008
20110224297Methods of administering prostratin and structural analogs thereof - This invention relates generally to methods for administering prostratin or a structural analog or metabolite thereof to induce latent HIV-1 expression in mammalian cells. In certain embodiments, prostratin or a structural analog or metabolite thereof is administered by infusion. In an exemplary embodiment, the method of administering prostratin or a structural analog or metabolite thereof to induce latent HIV-1 expression further comprises the step of administering HAART. The invention also relates to kits comprising prostratin or a structural analog or metabolite thereof packaged with instructions for infusing the compound to induce latent HIV-1 expression.09-15-2011
20130123357Methods for Providing Enhanced Resveratrol Activity Using 4-Acetoxy-Resveratrol - The present invention relates to a method of providing enhanced resveratrol activity comprising: administering a therapeutically effective amount of 4-acetoxy-resveratrol for the treatment of and preventing physiological and pathophysiological conditions mediated by (1) sirtuins, (2) estrogen and anti-estrogen hormone actions and (3) chemical interventions important for male and female health, aging, anti-aging and age-related disorders.05-16-2013
20110245338CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF - The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C10-06-2011
20090018192Methods for Repelling Arthropods Using Isolongifolenone Analogs - A method for for repelling arthropods involving treating an object or area with an arthropod repelling effective amount of at least one isolongifolenone analog (and optionally a carrier or carrier material).01-15-2009
20090215890GAMMA-HYDROXYBUTYRATE COMPOSITIONS CONTAINING CARBOHYDRATE, LIPID OR AMINO ACID CARRIERS - The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, or can target specific organs.08-27-2009
20130197082SHORT SYNTHESIS OF TOLTERODINE, INTERMEDIATES AND METABOLITES - A process is described for the preparation of intermediates which can be used for preparation of agents for urinary incontinence therapy, specifically to 2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol and its prodrugs.08-01-2013
20120046361ETHYL PYRUVATE COMPOSITIONS AND METHODS - Compositions and methods are disclosed for use of ethyl pyruvate to boost energy, endurance, or to feel good, or to lose weight. Pharmaceutical preparations having ethyl pyruvate are disclosed herein as well.02-23-2012

Patent applications in class ZC(=O)OY, wherein Z is an acyclic radical bonded to the C=O by a carbon and Y is an organic radical bonded to the oxygen by a carbon

Patent applications in all subclasses ZC(=O)OY, wherein Z is an acyclic radical bonded to the C=O by a carbon and Y is an organic radical bonded to the oxygen by a carbon